

## Contents

**Preface** XV

**List of Contributors** XVII

<b>1</b>	<b>Bioactive Phytocompounds: New Approaches in the Phytosciences</b>	<b>1</b>
	<i>Ricardo Ramos Mendonça-Filho</i>	
1.1	Introduction	2
1.2	Development of Fast Reliable Methods of Extraction and High-Throughput Screening (HTS) of Crude Plant Extracts: New Challenges	3
1.3	Antimicrobial Bioactive Phytocompounds from Extraction to Identification: Process Standardization	6
1.4	Problems Associated with the Efficacy, Stability and Quality Control of Herbal Drugs Preparations	13
1.5	Novel Bioactive Phytocompounds Against Multidrug-Resistant Bacteria/Fungi: The Management of Infectious and Chronic Diseases	17
1.6	Mode of Action of Bioactive Phytocompounds and their Interactions with Macromolecules and Toxicity	18
1.7	Bioactive Phytocompounds and Future Perspectives	21
	References	23
<b>2</b>	<b>Quality Control, Screening, Toxicity, and Regulation of Herbal Drugs</b>	<b>25</b>
	<i>Wickramasinghe M. Bandaranayake</i>	
2.1	Introduction	26
2.2	Preparation of Herbal Drugs	29
2.3	Quality Control of Herbal Drugs	30
2.3.1	Parameters for Quality Control of Herbal Drugs	34
2.3.1.1	Microscopic Evaluation	34
2.3.1.2	Determination of Foreign Matter	34
2.3.1.3	Determination of Ash	35
2.3.1.4	Determination of Heavy Metals	35

*Modern Phytomedicine. Turning Medicinal Plants into Drugs*

Edited by I. Ahmad, F. Aqil, and M. Owais

Copyright © 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

ISBN: 3-527-31530-6

2.3.1.5	Determination of Microbial Contaminants and Aflatoxins	35
2.3.1.6	Determination of Pesticide Residues	36
2.3.1.7	Determination of Radioactive Contamination	37
2.3.1.8	Analytical Methods	37
2.3.1.9	Validation	38
2.4	Herbal Supplements	39
2.5	Adulteration of Herbal Drugs	40
2.6	Contamination of Herbal Drugs and Herb–Drug Interactions	41
2.7	Toxicity of Herbal Drugs	43
2.8	Screening of Herbal Drugs	45
2.9	Labeling of Herbal Products	46
2.10	Policies and Regulations	47
2.11	Trends and Developments	49
2.12	Conclusions	50
	References	53
<b>3</b>	<b>Herbal Medicines: Prospects and Constraints</b>	<b>59</b>
	<i>Iqbal Ahmad, Farrukh Aqil, Farah Ahmad, and Mohammad Owais</i>	
3.1	Introduction	59
3.1.1	Traditional Systems of Medicine	61
3.1.1.1	Asian Medicinal System	61
3.1.1.2	European Herbalism	61
3.1.1.3	Neo-Western Herbalism	61
3.1.2	Modern Phytomedicine	61
3.2	Prospects for Herbal Medicine	62
3.2.1	Indian System-Based Herbal Medicine	64
3.2.2	Progress in the Pharmacokinetics and Bioavailability of Herbal Medicine	67
3.3	Constraints in Herbal Medicine	68
3.3.1	Reproducibility of Biological Activity of Herbal Extracts	68
3.3.2	Toxicity and Adverse Effects	68
3.3.3	Adulteration and Contamination	69
3.3.4	Herb–Drug Interactions	69
3.3.5	Standardization	71
3.3.6	Regulatory Challenges of Asian Herbal Medicine	71
3.4	Good Manufacturing Practice (GMP) for Herbal Medicine	72
3.5	Improving the Quality, Safety and Efficacy of Herbal Medicine	72
3.5.1	Quality Management	73
3.5.2	Encouraging Mediculture	73
3.5.3	Correct Identification of Plant Material	74
3.5.4	Minimizing Contamination in Herbal Medicine	74
3.6	Conclusions	74
	Acknowledgments	75
	References	76

## **4 Bioactive Phytocompounds and Products Traditionally Used in Japan 79**

*Jin-ichi Sasaki*

- 4.1 Introduction 80
- 4.2 Garlic 80
  - 4.2.1 Introduction 80
  - 4.2.2 Biological Effect of Garlic 81
    - 4.2.2.1 Antibacterial Effects 81
    - 4.2.2.2 Anticoagulation Effects 84
    - 4.2.2.3 Antioxidant Activity 86
    - 4.2.2.4 Therapeutic Effects of Garlic Powder in the Organophosphate Compound Poisoning Mouse as a Model of SARS 87
- 4.3 Mushroom 87
  - 4.3.1 Introduction 87
  - 4.3.2 Biological Effects 88
    - 4.3.2.1 Antitumor Activity 88
- 4.4 Sweetcorn 92
  - 4.4.1 Introduction 92
  - 4.4.2 Biological Effects 92
    - 4.4.2.1 Antitumor Activity of Sweetcorn 92
- 4.5 Oil and Flavor of Tree Hiba (Japanese Cypress) (Hinokitiol) 94
  - 4.5.1 Introduction 94
  - 4.5.2 Biological Effects 94
- 4.6 Conclusions 95
- Acknowledgments 96
- References 96

## **5 Plant Extracts Used to Manage Bacterial, Fungal, and Parasitic Infections in Southern Africa 97**

*J.N. Eloff and L.J. McGaw*

- 5.1 Introduction 98
- 5.2 Biodiversity in Southern Africa 99
- 5.3 Use of Plants in Southern African Traditional Medicine 99
- 5.4 The Need for Anti-Infective Agents 100
- 5.5 Selection of Plant Species to Investigate 100
  - 5.5.1 Ethnobotanical Approach 101
  - 5.5.2 Chemotaxonomy 101
  - 5.5.3 Random Selection 101
- 5.6 Collecting, Drying, and Storage of Plant Material 102
- 5.7 Extraction of Plant Material 103
  - 5.7.1 Which is the Best Extractant? 103
  - 5.7.2 Extraction Period and Efficiency 104
  - 5.7.3 Selective Extraction 104
  - 5.7.4 Redissolving Extracts for Quantitative Data 105
  - 5.7.5 Storage of Extracts 105
- 5.8 Evaluating Quantitative Antimicrobial Activity 105

5.9	Evaluating Qualitative Biological Activity	106
5.10	Expression of Results	107
5.11	Antibacterial Activity	108
5.12	Results on Antibacterial Activity Obtained with Members of the Combretaceae	109
5.12.1	Introduction	109
5.12.2	<i>Combretum erythrophyllum</i>	109
5.12.3	Antibacterial Activity of Southern African Members of the Combretaceae	109
5.12.4	Stability of Extracts	110
5.12.5	Anti-Inflammatory Activity	110
5.12.6	Other Activities of Extracts of Combretum Species	111
5.12.7	Isolation and Biological Activity of Antibacterial Compounds from <i>C. erythrophyllum</i>	111
5.12.8	<i>Combretum woodii</i>	111
5.12.9	Unpublished Work on Other Members of the Combretaceae	112
5.13	Antifungal Activity	112
5.14	Antiparasitic Activity	113
5.15	Other Anti-Infective Research in South Africa	115
5.16	Cytotoxicity	115
5.17	Ethnoveterinary Research	116
5.18	Determining the <i>in vivo</i> Efficacy of Extracts and Isolated Compounds	117
5.19	Conclusion	118
	References	119
<b>6</b>	<b>Biological and Toxicological Properties of Moroccan Plant Extracts: Advances in Research</b>	<b>123</b>
	<i>M. Larhsini</i>	
6.1	Introduction	123
6.2	Ethnobotanic and Ethnopharmacology of Traditional Moroccan Plants	125
6.2.1	Ethnobotanic Surveys	125
6.2.2	Biological Activities	126
6.2.2.1	Antimicrobial Properties	126
6.2.2.2	Antidiabetic Activity	128
6.2.2.3	Other Biological Activities	131
6.3	Toxicological Assays	131
6.4	Conclusions	132
	References	133
<b>7</b>	<b>Anti-MRSA and Anti-VRE Activities of Phytoalexins and Phytoncides Isolated from Tropical Plants</b>	<b>137</b>
	<i>Yoshikazu Sakagami</i>	
	Introduction	138

7.2	Phytoalexins and Phytoncides	139
7.3	Antibiotics	140
7.4	Bacteria and Broth	140
7.4.1	VRE	140
7.4.2	VSE	141
7.4.3	MRSA	141
7.4.4	MSSA	141
7.4.5	Broth	141
7.5	Isolation of Phytoalexins and Phytoncides	141
7.6	Minimum Inhibitory Concentration	142
7.7	Synergism of Antibacterial Compounds with Commercially Available Antibiotics	142
7.8	Antibacterial Activities	143
7.8.1	Sophoraflavanone G	143
7.8.2	Calozyloxanthone	144
7.8.3	a-Mangostin	144
7.8.4	Gnemonol B and Gnetin E	145
7.8.5	Summary of MIC Values of Phytoalexin and Phytoncide Against MRSA and VRE	146
7.9	Synergism Between the Test Compounds and Commercial Antibiotics Against VRE, MRSA, VSE, and MSSA	147
7.9.1	Sophoraflavanone G	147
7.9.2	Calozyloxanthone	148
7.9.3	a-Mangostin	148
7.9.4	Stilbene Oligomer	151
7.9.5	Summary of Synergistic Effects Between the Test Compounds and the Commercial Antibiotics Against VRE and MRSA	153
	References	154
<b>8</b>	<b>Methods for Testing the Antimicrobial Activity of Extracts</b>	<b>157</b>
	<i>Jenny M. Wilkinson</i>	
8.1	Introduction	157
8.2	Antibacterial Assays	158
8.2.1	Semi-Solid Substrate Methods	161
8.2.1.1	Disk Diffusion Method	161
8.2.1.2	Agar Dilution Method	162
8.2.1.3	Broth Dilution Methods	163
8.2.1.4	Thin-Layer Chromatography–Bioautography	164
8.3	Antifungal Assays	165
8.4	<i>In vivo</i> Assessment of Antibacterial and Antifungal Activity	166
8.5	Methods for Assessing Antiviral Activity	167
8.6	Screening of Plant Extracts for Antiparasitic Activity	167
8.7	Conclusions	168
	References	169

<b>9</b>	<b>Targeted Screening of Bioactive Plant Extracts and Phytocompounds Against Problematic Croups of Multidrug-Resistant Bacteria</b>	<b>173</b>
	<i>Farrukh Aqil, Iqbal Ahmad, and Mohammad Owais</i>	
9.1	Introduction	174
9.1.1	Multiple Antibiotic Resistance in Bacteria	174
9.1.2	Plants as a Source of Novel Bioactive compounds	177
9.2	Approaches to Targeted Screening Against MDR Bacteria	179
9.2.1	MDR Efflux Pump Inhibitors from Plants	180
9.2.2	$\beta$ -Lactamase Inhibitors	181
9.2.3	Synergy Between Phytocompounds and Antibiotics	182
9.2.4	Targeting Virulence and Pathogenicity	185
9.2.5	Quorum Sensing Inhibitors	186
9.3	Other Potential Approaches	189
9.3.1	Targeting Gene Transfer Mechanisms	189
9.3.2	Targeting R-Plasmid Elimination	190
9.4	Conclusions and Future Directions	191
	Acknowledgments	192
	References	193
<b>10</b>	<b>Activity of Plant Extracts and Plant-Derived Compounds against Drug-Resistant Microorganisms</b>	<b>199</b>
	<i>Antonia Nostro</i>	
10.1	Introduction	199
10.2	Plant Materials with General Antimicrobial Activity Including some Drug-Resistant Strains	200
10.3	Plant Materials with Specific Antimicrobial Activity Against Drug-Resistant Strains	201
10.3.1	Drug-Resistant Gram-Positive Bacteria	201
10.3.2	Drug-Resistant Gram-Negative Bacteria	211
10.3.3	Other Drug-Resistant Microorganisms	212
10.4	Plant Materials that Restore the Effectiveness of Antimicrobial Agents and/or Inhibit Drug Resistance Mechanisms	223
10.4.1	Other Mechanisms	225
10.5	Conclusions	226
	References	226
<b>11</b>	<b>An Alternative Holistic Medicinal Approach to the Total Management of Hepatic Disorders: A Novel Polyherbal Formulation</b>	<b>233</b>
	<i>Mohammad Owais, Iqbal Ahmad, Shazia Khan, Umber Khan, and Nadeem Ahmad</i>	
11.1	Introduction	233
11.2	Conventional Medicines for Liver Disorders	236
11.3	Herbal Medicines – Potential Therapeutic Agents with Minimal Side-Effects	237

- 11.4 Contributions of Elementology to Potential Treatments for Hepatic Disorders 240
- 11.5 Other Alternatives in Liver Therapy 242
- 11.6 Conclusions 242
- References 243

## **12 Traditional Plants and Herbal Remedies Used in the Treatment of Diarrheal Disease: Mode of Action, Quality, Efficacy, and Safety Considerations 247**

*Enzo A. Palombo*

- 12.1 Introduction 248
- 12.2 Methods Used in the Evaluation of Bioactivity of Medicinal Plants 249
  - 12.2.1 Antibacterial Activity 249
  - 12.2.2 Antiprotozoal Activity 250
  - 12.2.3 Anthelmintic Activity 250
  - 12.2.4 Antiviral Activity 250
  - 12.2.5 Antidiarrheal Activity 251
- 12.3 Traditional Medicinal Plants Used in the Treatment of Diarrhea that Display Antimicrobial Activity 252
- 12.4 Traditional Medicinal Plants Used in the Treatment of Diarrhea that Display Antidiarrheal Activity 255
- 12.5 Phytochemical Analysis, Identification of Active Plant Components, and Mechanism of Action of Medicinal Plants Used in the Treatment of Diarrhea 260
- 12.6 Quality, Efficacy, and Safety Considerations 263
- 12.7 Conclusions 266
- Acknowledgments 267
- References 267

## **13 Mutagenicity and Antimutagenicity of Medicinal Plants 271**

*Javed Musarrat, Farrukh Aqil, and Iqbal Ahmad*

- 13.1 Introduction 271
- 13.2 Plants as Protective Agents Against DNA Damage 272
- 13.3 Antimutagenic Properties of Edible and Medicinal Plants 274
- 13.4 Mutagenicity of Plant Extracts and Phytocompounds 279
- 13.5 "Janus Carcinogens and Mutagens" 280
- 13.6 Chemical Nature of Phytoantimutagenic Compounds 281
  - 13.6.1 Flavonoids 282
  - 13.6.2 Phenolic Compounds 282
  - 13.6.3 Coumarins 282
  - 13.6.4 Diterpenoids 282
  - 13.6.5 Organosulfur Compounds 283
- 13.7 Assays for Mutagenicity and Antimutagenicity 283
- 13.8 Paradigms in Antimutagenicity Research 285

<b>13.9</b>	Conclusions	285
	References	286
<b>14</b>	<b>Potential of Plant-Derived Products in the Treatment of Mycobacterial Infections</b>	293
	<i>Deepa Bisht, Mohammad Owais, and K. Venkatesan</i>	
14.1	Introduction	293
14.2	Current Therapy of Tuberculosis and Leprosy	294
14.3	Need for Newer Antimycobacterial Drugs	295
14.4	Plant Extracts	295
14.5	Well-Characterized Plant-Derived Compounds	297
14.5.1	Alkanes, Alkenes, Alkynes, Fatty Acids and their Esters and Simple Aromatics	297
14.5.2	Alkaloids	299
14.5.3	Phenolics and Acetogenic Quinones	302
14.5.4	Terpenes	304
14.5.5	Steroids	308
14.6	Conclusion	308
	Acknowledgements	309
	References	309
<b>15</b>	<b>Ethnomedicinal Antivirals: Scope and Opportunity</b>	313
	<i>Debprasad Chattopadhyay</i>	
15.1	Introduction	313
15.1.1	Ethnomedicines and Drug Discovery	314
15.1.2	Viruses: The Acellular Parasite of Cellular Hosts	315
15.1.2.1	Viral Infection Control	316
15.2	Antiviral Ethnomedicines Against Common Virus Families	316
15.3	Major Groups of Antivirals from Plants	321
15.3.1	Phenolics and Polyphenols	322
15.3.2	Coumarins	323
15.3.3	Quinones	324
15.3.4	Flavones, Flavonoids, and Flavonols	324
15.3.5	Tannins	327
15.3.6	Lignans	327
15.3.7	Terpenoids and Essential Oils	328
15.3.8	Alkaloids	329
15.3.9	Lectins, Polypeptides and Sugar-Containing Compounds	330
15.4	Mixtures and Other Compounds	330
15.5	Experimental Approaches	331
15.5.1	<i>In Vitro</i> Efficacy	331
15.5.2	Clinical Trials in Humans	332
15.6	Future Prospects	334
15.7	Conclusions	334
	Acknowledgments	335
	References	335



<b>16</b>	<b>Immunomodulatory Effects of Phytochemicals</b>	<b>341</b>
	<i>Buket Cicioğlu Ardoğan</i>	
16.1	Introduction	342
16.1.1	General Properties and Classification of Phytochemicals	342
16.2	Effect of Specific Medicinal Herbs on Immune System and Immune Cells	343
16.3	General Properties of Echinacea Species	344
16.4	Effects of Echinacea Species on the Immune System and Various Immune Cells	345
16.5	Asteraceae	349
16.6	<i>Lithospermum erythrorhizon</i>	351
16.7	Guarana	352
16.8	Side and Adverse Effects of Some Phytochemicals	352
16.9	Conclusion	353
	References	354
<b>17</b>	<b>Use of a Liposomal Delivery System for Herbal-Based Therapeutics (with a Focus on Clove Oil)</b>	<b>357</b>
	<i>Nadeem Ahmad, Maroof Alam, Iqbal Ahmad, and Mohammad Owais</i>	
17.1	Introduction	357
17.1.1	Cinnamon Oil	359
17.1.2	Oregano Oil	359
17.1.3	Clove Oil	359
17.1.3.1	Composition of the Clove Oil Used	360
17.2	Rationale for Using Liposomal Formulation of Clove Oil	361
17.2.1	Advantageous Properties of Liposomes	362
17.3	Experiments Conducted to Develop Liposomal Clove Oil Formulation	362
17.3.1	Determination of MIC of Clove Oil against <i>Candida albicans</i>	363
17.3.2	Determination of MIC of Clove Oil against <i>Escherichia coli</i>	363
17.3.3	<i>In Vitro</i> Antibacterial Activity Test Results	363
17.3.4	<i>In Vitro</i> Antifungal Activity Tests Results (Table 17.4)	364
17.3.5	<i>In Vivo</i> Antifungal Activity Test Results against Experimental Vaginal Candidiasis	364
17.3.5.1	Evaluation of Efficacy of Liposomal Clove Oil	364
17.3.5.2	Evaluation of Route of Administration	365
17.4	Conclusions	366
	References	366
	<b>Subject Index</b>	<b>369</b>